e Company may
encounter in the development of the PCT technology and the PCT Sample
Preparation System; the possibility that other laboratories may be unable
to duplicate the results generated by Dr. Pevsner and his colleagues; the
possibility that the data generated may not be beneficial in the
development of new therapeutics and diagnostics for stroke, colon cancer,
and embryo viability; that due to competitive products, services, and
technological advances, PCT may not be the preferred method of sample
preparation by other scientists and laboratories; and the other risks and
uncertainties discussed under the heading "Risk Factors" in the Company's
Annual Report on Form 10-KSB for the year ended December 31, 2006, and
other reports filed by the Company from time to time with the SEC. The
Company undertakes no obligation to update any of the information included
in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Senior Vice President of Finance & CFO
Pressure BioSciences, Inc.
(508) 580-1818 (T)
'/>"/>SOURCE Pressure BioSciences, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
The TripleMaster PCR System for three different amplifications2.
Cloning Based on Efficient Three-Fragment Assembly
DNA Ligation3.
Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS4.
Three finalists named for UW-Madison CIO5.
Three state businesses receive technology grants6.
Leading cancer institute to install three TomoTherapy systems7.
Waukesha considers wireless bids from three firms8.
Computerworld top 100 includes three Wisconsin CIOs9.
30 days to success: Three simple steps to create your own international startup10.
Three firms get state tech development grants11.
Three more Wisconsin firms to present at venture forum